Next 10 |
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (C...
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to...
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients. ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharm...
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing period Achieved ...
2023-11-03 12:14:31 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (...
2023-11-03 09:53:11 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (NASDAQ: TNO...
2023-11-03 08:18:52 ET Werewolf Therapeutics ( HOWL ) +38% jumps on early-sage data from lead program. DigitalOcean Holdings ( DOCN ) +23% stock jumps 20%, guides Q4 and FY figures above consensus. InflaRx ( IFRX ) +16% . Block ( SQ ) +1...
InflaRx N.V. (IFRX) is expected to report $-0.29 for Q3 2023
2023-11-01 07:46:02 ET More on InflaRx InflaRx: Small German Company Targeting A Rare Indication EU regulators accept InflaRX vilobelimab application for review Seeking Alpha’s Quant Rating on InflaRx Historical earnings data for InflaRx Financ...
News, Short Squeeze, Breakout and More Instantly...
InflaRx N.V. Company Name:
IFRX Stock Symbol:
NASDAQ Market:
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...